Pacritinib versus best available therapy for the treatment of myelofibrosis irrespective of baseline cytopenias (PERSIST-1): an international, randomised, phase 3 trial
Background: Available therapies for myelofibrosis may exacerbate cytopenias and are not indicated for patients with severe thrombocytopenia. The JAK2/FLT3 inhibitor pacritinib induced spleen responses with limited myelosuppression in phase 1/2 trials. We aimed to assess the efficacy and safety of pacritinib vs best available therapy in patients with myelofibrosis irrespective of baseline cytopenias.Expand abstract
Methods: In the international phase 3 PERSIST-1 trial, patients with higher-risk m...
- Publication status:
- Peer review status:
- Peer reviewed
(Accepted manuscript, pdf, 2.0MB)
- Publisher copy:
- Copyright holder:
- Copyright date:
- © 2017 Elsevier Ltd. All rights reserved. This is the accepted manuscript version of the article. The final version is available online from Elsevier at: [10.1016/S2352-3026(17)30027-3].